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Introduction
Fragile X syndrome (FXS, MIM # 309550), is the most 
common inherited form of mental retardation. It has an 
estimated frequency of 1/7000 males and 1/11,000 women 
[1]. Affected males display varying degrees of symptoms 
ranging from mild to severe [2]. The behaviour of boys 
with FXS typically includes attention deficit hyperactivity 
disorder (ADHD) with significant impulsivity and anxiety, 
as well as repetitive language and hand stereotypes. Spe-
cific behaviour combined with social and language defi-
cits, often lead to a diagnosis of autism spectrum disorder 
(ASD) before the FXS is diagnosed [2]. The Fragile X syn-
drome is the most common single genetic cause of autism, 
occurring in 1–6 % of boys with ASD [3]. In almost all 
cases the disease is caused by an expansion of the unstable 
CGG repeat sequence located in the 5′ untranslated region 
of the FMR1 gene [4]. In affected individuals the CGG 
repeat length exceeds 200 and is called the full mutation 
(FM). The promoter pf the FMR1 gene is usually hyper-
methylated and the methylation involves also the adjacent 
promoter region of the FMR1 gene. The gene is transcrip-
tionally silenced and the gene product, the Fragile X men-
tal retardation protein (FMRP), is absent [5].
Loss of FMRP, an RNA binding protein, which is a neg-
ative regulator of group I mGluR results in increased syn-
thesis of proteins normally regulated by FMRP, dysregula-
tion of synaptic signal transduction and channel function, 
excess mGluR signalling and dysfunction of synaptic plas-
ticity [6].
A spectrum of medical problems in fragile X syndrome 
patients has been reported, such as seizures, recurrent otitis 
media, gastrointestinal disturbances. The behavioural phe-
notype of FXS includes significant anxiety, poor eye con-
tact, attention deficit hyperactivity, hyperarousal to sensory 
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stimuli, irritability, repetitive motor behaviors. Ocular dis-
orders are common in FXS patients. Many of them need 
glasses because of refractive errors. Sleep problems are 
observed in 10–25 % of children and adolescents. Loud 
snoring and obstructive sleep apnoea occurred in 38 and 
34 % of children with FXS [7].
We found only one study describing cholesterol levels in 
adult individuals with FXS. The Berry-Kravis study in [8] 
described cholesterol levels in both children and adults.
To confirm and extend these findings, we prospectively 
measured serum levels of total cholesterol (TC), high-den-
sity cholesterol fraction (HDL-C), low-density cholesterol 
fraction (LDL-C) and triacylglycerols, in 23 males with 
FXS and 24 age-matched controls.
Study Participants and Methods
The study was conducted at the Department of Molecular 
Biology and Genetics, Silesian Medical University School 
of Medicine in Katowice, from February to May 2012.
Twenty three male patients, mean age 19.3 ± 6.6, 
affected by Fragile X syndrome, confirmed by detection 
of full mutation in the FMR1 gene, were recruited through 
registry databases maintained by Medical University of 
Silesia, Upper Silesia Center of the Children’s Health John 
Paul II in Katowice. All participants harboured the “full 
mutation” form of the FMR1 gene. Diagnosis of Fragile 
X syndrome was based on clinical criteria and molecular 
analysis of the FMR1 gene. The control group comprised 
24 healthy males, mean age 21.8 ± 5.8 years. The study 
protocols were approved by the local Ethical Committee 
of the Faculty of Medicine, Medical University of Silesia 
in Katowice. In addition, an informed written parental/
legal guardian consent was obtained from the parents/legal 
guardians of the studied subjects.
A complete medical evaluation, including medical his-
tory, family history, psychological testing and physical 
examination were conducted for each subject. The patients 
and controls were not taking any lipid-modifying drugs.
Venous blood samples were drawn from each subject by 
venipuncture into a sodium heparin tube between 8 and 10 
am after having been instructed to fast the previous 12 h. 
Then the blood was centrifuged at 3000×g for 10 min. 
Plasma was collected and stored at −80 °C until further 
study.
Serum total cholesterol (TC), triacylglycerols, high-den-
sity cholesterol fraction (HDL-C), low-density cholesterol 
fraction (LDL-C) were determined in all the study partici-
pants. Triacylglycerols, TC and HDL-C were measured by 
an enzymatic colorimetric method using the BM Roche/
Hitachi 717 analyzer (kits of Roche). LDL-C was calcu-
lated using the formula LDL-C = TC − HDL-C − triacyl-
glycerols/5 [9].
Statistical Analysis
Data are presented as means ± standard deviations. The 
Kolmogorov–Smirnov test was used to determine whether 
continuous variables are normally distributed. Differences 
between normally distributed variables were assessed with 
the independent samples t test. The Mann–Whitney U test 
was used to examine all non-normal continuous variables 
and Spearman’s non-parametric correlation coefficient to 
calculate correlations. For all tests, a probability (p) of less 
than 0.05 was considered statistically significant. Statisti-
cal analyses were performed with SPSS statistics software, 
version 10 (StatSoft. Inc. DELL, USA).
Results
Patients and controls were matched for age. The demo-
graphic and anthropometric data are shown in Table 1. 
Serum lipid profiles are shown in Table 2. The results are 
presented as means and standard deviations. Overweight 
and obesity were observed in 60.86 % of FXS group.
Comparison of the TC, HDL, LDL and triacylglycerols, 
values from FXS patients to those from the control group 
showed that mean values of the serum levels of HDL-C 
were significantly lower in FXS patients (43.4 ± 7.0 FXS 
vs 56.3 ± 12.6 control, p < 0.001), the serum levels of tria-
cylglycerols, were higher in FXS patients (133.3 ± 57.2 
FXS vs 94.7 ± 64.6 controls, p = 0.035). The TC and 
LDL-C levels did not differ statistically from the controls. 
There was no significant correlation between BMI and TC, 
HDL-C or LDL-C levels in FXS group. HDL/LDL did not 
differ statistically.
Table 1  Dermographic characteristics of patients with FXS and con-
trols
FXS group Control group p
X ± SD Range X ± SD Range
Age (years) 19.3 ± 6.6 10–32 21.8 ± 5.8 8–29 0.07
Body mass 
(kg)
77.6 ± 21.1 28.0–103.5 71.5 ± 19.4 22.0–94.0 0.1
Height (cm) 170 ± 15 120–150 173 ± 17 119–192 0.1
BMI 26.5 ± 4.7 18.5–34.9 22.9 ± 3.4 14.9–27.7 0.01
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Discussion
This study analysed the serum levels of total cholesterol 
(TC), triacylglycerols, high-density cholesterol frac-
tion (HDL-C), low-density cholesterol fraction (LDL-C) 
in FXS patients and used an age-matched control group. 
Results indicated that the serum levels of HDL-C were 
lower in FXS patients and serum levels of triacylglycerols 
were higher in FXS patients compared to the control group. 
HDL-C was more significantly reduced relative to the con-
trols. The TC and LDL-C levels were lower in the FXS 
group, but the difference was not statistically significant.
Berry-Kravis et al. [8] performed a chart review to col-
lect information on cholesterol levels from patients with 
FXS attending the clinic program. This retrospective study 
strongly suggested that TC, HDL-C and LDL-C levels were 
lower in males with FXS than normative population data. 
Our prospective study confirmed the previously reported 
low HDL-C in FXS but was not powered to detect a signifi-
cant difference in TC and LDL-C because the amount of 
difference was less than for HDL-C.
There was no significant correlation between BMI and 
TC, HDL-C or LDL-C levels in FXS group. Our observa-
tions confirmed the lack of relationship between BMI and 
lipid levels in FXS observed by Berry-Kravis et al. [8].
HDL-C are remarkably complex, dynamic and heteroge-
neous particles defined by the density range 1063–1.21 g/
ml. Serum levels of HDL-C are inversely related to risk 
of atherosclerotic cardiovascular disease. Among patients 
with premature cardiovascular disease, low HDL-C is the 
most common lipid abnormality. However, data from recent 
clinical trials, which used various methods to raise HDL-C 
levels have not showed the expected improvement in CVD. 
HDL-C has long been known to have anti-inflammatory 
properties, but during the acute inflammatory response, 
HDL changes to a pro-inflammatory state [10].
The observation that the serum levels of HDL-C are 
lower and serum levels of triacylglycerols, are higher in 
FXS patients has implications for health monitoring and 
treatment practices. The low HDL-C may be risk factor for 
development of vascular and/or cardiac disorders. Accord-
ing to the guidelines for health supervision of patients with 
FXS growth and weight parameters, auscultation of the 
heart and blood pressure values should be obtained at clinic 
visits. Standard monitoring of lipid profiles in FXS patients 
should be also involved in health supervision [11].
FMRP is an RNA-binding protein that regulates stim-
ulus-dependent translation of a large number of proteins. 
Misregulation of one or many proteins which in normal 
situation are regulated by FMRP may be responsible for the 
lower HDL and higher TG observed in FXS patients. The 
recent analysis of the genes involved in lipid homeostasis 
revealed that several FMRP target genes are linked to regu-
lation of lipid levels, including APOE, GSK3B [12–14]
This study is limited by a relatively small sample size. 
The nearly significant difference between the age of the 
FXS and control group may be a limitation of the study. 
The lipid levels vary with age, especially in children and 
adolescents. Further studies are needed to confirm the 
results in a larger prospective study group. Further study 
involving larger samples are necessary to confirm the 
results and define the health implications for abnormal lipid 
levels in FXS patients.
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